"This new asleep procedure allows us to approach a larger group of patients who would have previously declined the treatment," says Dr. Sadreddin. "It is a real breakthrough for those who are anxious about having awake brain surgery, and for patients like Tommy who are young, healthy and have lesser chance of side effects from general anesthesia."
While DBS has been around for a number of years, the surgeons at Barrow have taken it to a new level by allowing patients to "sleep" during the procedure. Today Barrow surgeons are performing more DBS procedures than at any hospital in the nation and Barrow is one of only a handful of institutions to offer the "asleep" procedure.
Last year, Zuleger began to prepare for the surgery as a patient in the Ali center's new DBS Clinic. "After doing a lot of research, it didn't sound as scary, and actually began to look more and more promising."
Zuleger had the surgery last October and is now back to work and loving life with his wife and four children. "My whole world changed. It was like someone was flipping a switch on in my brain. I know that DBS isn't a cure, but I feel better than I have in years and I hope that it will help to control my symptoms for years to come."
Dr. Sadreddin emphasizes that there is still no cure for Parkinson's disease and DBS is not an effective treatment for all patients. She adds, however, that this new procedure can allow more patients the opportunity to benefit from an improved quality of life they would not have enjoyed previously on medication alone.
About Barrow Neurological Institute
Home to the Muhammad Ali Parkinson Center, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix,
SOURCE St. Joseph's Hospital and Medical Center
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Deep Brain Stimulation Clinic Expedites Patient Treatment at Muhammad Ali Parkinson Center
2. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
3. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
4. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
5. From Autism to Diabetes to Parkinsons Disease: Pew Funds 22 Early-Career Scientists to Take Calculated Risks
6. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
7. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
8. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
9. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
10. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
11. Dont Get Sacked by Parkinsons - Know the Full Range of Symptoms